ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
Rhea-AI Summary
ImageneBio (Nasdaq: IMA) announced that CEO Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 12:50 PM EDT. A live webcast and 90-day archive will be available on the Imagene investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – IMA
In the May 28 session, IMA declined 0.08%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 7 | Earnings and update | Positive | -10.5% | Q1 2026 results, cash runway into Q1 2028, IMG-007 Phase 2b timing. |
| Apr 13 | Private placement | Positive | +23.4% | $30M private placement to fund IMG-007 alopecia and dermatitis work. |
| Mar 17 | Equity inducement grants | Neutral | -3.2% | Inducement RSUs and NSOs granted to new hires under 2025 plan. |
| Mar 10 | Earnings and update | Positive | +2.5% | Q4 and 2025 results, IMG-007 Phase 2b enrollment and cash position. |
| Feb 26 | Conference participation | Neutral | +1.6% | Participation in Leerink Global Healthcare Conference and fireside chat. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Funding and capital markets events (notably the April 2026 private placement and related filings) have coincided with the strongest positive moves, while earnings and program updates have sometimes seen negative or modest reactions.
Over the last few months, ImageneBio has focused on financing and advancing its lead asset IMG-007. A $30 million private placement on Apr 13, 2026 preceded a strong positive move, while Q1 2026 earnings and program updates on May 7, 2026 saw a -10.49% reaction despite extended cash runway guidance. Earlier, Q4 2025 earnings on Mar 10, 2026 drew a modest gain, and a Leerink conference appearance on Feb 26, 2026 saw a small positive move. Today’s Jefferies conference news continues this pattern of active investor-relations outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.
Jefferies Global Healthcare Conference in New York
Date: Thursday, June 4, 2026
Time: 12:50 PM EDT
Webcast: Linked here and archived for 90 days on events page on the Imagene IR website
About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targeting, non-T cell-depleting, ADCC-silenced, anti-OX40 monoclonal antibody with an approximately 5-week half-life. Imagene is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. The Company has also completed a proof-of-concept trial and plans to initiate a Phase 2 study in alopecia areata.
Company and Investor Contact
Rebecca Cohen
rcohen@imagenebio.com
Media Contact
Jason Braco, PhD
The Health & Science Agency
jason@healthscienceagency.com
